• Curis priced an $8.5 million private placement with existing healthcare-focused institutional investors, expected to close around October 19, 2026.
• The offering comprises 16,666,680 common shares or pre-funded warrants at $0.51 each, including an accompanying common warrant.
• Common warrants cover 16,666,680 shares at $0.60 each, becoming exercisable after six months and expiring five-and-a-half years from issuance.
• Existing January 2026 and August 2026 warrants will have exercise prices reduced to $0.60 from $15 and $1.75, respectively.
• Proceeds will fund research and operations through initial chronic lymphocytic leukemia data from 5-10 patients expected in December 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610160800PR_NEWS_USPR_____NE74019) on October 16, 2026, and is solely responsible for the information contained therein.